N-[7-(hydroxyamino)-7-oxoheptyl]-N-methylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[7-(hydroxyamino)-7-oxoheptyl]-N-methylbenzamide
• 化学式: C₁₅H₂₂N₂O₃
• 分子量: 278.35
• InChiKey: OUGOXQQQKCVHKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS
  申请人：Acetylon Pharmaceuticals, Inc.

  公开号：EP2839037A1

  公开（公告）日：2015-02-25
• [EN] BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS<br/>[FR] BIOMARQUEURS PERMETTANT D'IDENTIFIER DES PATIENTS QUI RÉAGIRONT À UN TRAITEMENT, ET TRAITEMENT DESDITS PATIENTS
  申请人：ACETYLON PHARMACEUTICALS INC

  公开号：WO2013158984A1

  公开（公告）日：2013-10-24

  The invention relates to methods for using biomarkers to identify cancer patients that will or are likely to respond to treatment. Specifically, the invention relates to the use of one or more of three association studies of cancer types, gene mutations, or gene expression levels in order to identify cancer patients that will or are likely to respond to treatment with a histone deacetylase (HDAC) inhibitor, alone or in combination with another cancer treatment. The methods may, optionally, further include treating such patient with an HDAC inhibitor, alone or in combination with another cancer treatment.